Logo image of IVVD

INVIVYD INC (IVVD) Stock Fundamental Analysis

NASDAQ:IVVD - Nasdaq - US00534A1025 - Common Stock - Currency: USD

0.9791  +0.14 (+16.87%)

Fundamental Rating

3

Taking everything into account, IVVD scores 3 out of 10 in our fundamental rating. IVVD was compared to 562 industry peers in the Biotechnology industry. The financial health of IVVD is average, but there are quite some concerns on its profitability. IVVD has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IVVD had negative earnings in the past year.
IVVD had a negative operating cash flow in the past year.
In the past 5 years IVVD always reported negative net income.
IVVD had a negative operating cash flow in each of the past 5 years.
IVVD Yearly Net Income VS EBIT VS OCF VS FCFIVVD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of IVVD (-131.20%) is worse than 82.21% of its industry peers.
IVVD has a Return On Equity of -251.59%. This is in the lower half of the industry: IVVD underperforms 72.78% of its industry peers.
Industry RankSector Rank
ROA -131.2%
ROE -251.59%
ROIC N/A
ROA(3y)-93.62%
ROA(5y)-74.61%
ROE(3y)-143.77%
ROE(5y)-106.92%
ROIC(3y)N/A
ROIC(5y)N/A
IVVD Yearly ROA, ROE, ROICIVVD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

IVVD has a Gross Margin of 93.63%. This is amongst the best in the industry. IVVD outperforms 93.95% of its industry peers.
IVVD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVVD Yearly Profit, Operating, Gross MarginsIVVD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

IVVD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IVVD has more shares outstanding
There is no outstanding debt for IVVD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IVVD Yearly Shares OutstandingIVVD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
IVVD Yearly Total Debt VS Total AssetsIVVD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

IVVD has an Altman-Z score of -12.73. This is a bad value and indicates that IVVD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IVVD (-12.73) is worse than 78.83% of its industry peers.
There is no outstanding debt for IVVD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.73
ROIC/WACCN/A
WACC10.03%
IVVD Yearly LT Debt VS Equity VS FCFIVVD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

IVVD has a Current Ratio of 1.62. This is a normal value and indicates that IVVD is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IVVD (1.62) is worse than 80.43% of its industry peers.
A Quick Ratio of 1.62 indicates that IVVD should not have too much problems paying its short term obligations.
The Quick ratio of IVVD (1.62) is worse than 79.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
IVVD Yearly Current Assets VS Current LiabilitesIVVD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.68% over the past year.
EPS 1Y (TTM)17.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IVVD will show a very strong growth in Earnings Per Share. The EPS will grow by 34.21% on average per year.
The Revenue is expected to grow by 94.57% on average over the next years. This is a very strong growth
EPS Next Y107.76%
EPS Next 2Y60.97%
EPS Next 3Y44.44%
EPS Next 5Y34.21%
Revenue Next Year599.08%
Revenue Next 2Y257.97%
Revenue Next 3Y174.3%
Revenue Next 5Y94.57%

3.3 Evolution

IVVD Yearly Revenue VS EstimatesIVVD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IVVD Yearly EPS VS EstimatesIVVD Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

IVVD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.47, the valuation of IVVD can be described as reasonable.
98.04% of the companies in the same industry are more expensive than IVVD, based on the Price/Forward Earnings ratio.
IVVD is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.47
IVVD Price Earnings VS Forward Price EarningsIVVD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVVD Per share dataIVVD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

IVVD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IVVD's earnings are expected to grow with 44.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.97%
EPS Next 3Y44.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IVVD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVIVYD INC

NASDAQ:IVVD (5/13/2025, 9:57:04 AM)

0.9791

+0.14 (+16.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/bmo
Earnings (Next)05-15 2025-05-15/amc
Inst Owners79.43%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change0%
Market Cap117.45M
Analysts80
Price Target6.73 (587.37%)
Short Float %10.86%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.09%
Min EPS beat(2)-48.15%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-7.77%
Min EPS beat(4)-48.15%
Max EPS beat(4)20.17%
EPS beat(8)3
Avg EPS beat(8)-11.59%
EPS beat(12)6
Avg EPS beat(12)-2.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33.34%
Min Revenue beat(2)-66.54%
Max Revenue beat(2)-0.13%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-79.96%
EPS NY rev (1m)0%
EPS NY rev (3m)196.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.47
P/S 4.63
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-1.49
EYN/A
EPS(NY)0.12
Fwd EY11.81%
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.42
OCFYN/A
SpS0.21
BVpS0.56
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -131.2%
ROE -251.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.63%
FCFM N/A
ROA(3y)-93.62%
ROA(5y)-74.61%
ROE(3y)-143.77%
ROE(5y)-106.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.5%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -12.73
F-Score3
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)1436.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.15%
EPS Next Y107.76%
EPS Next 2Y60.97%
EPS Next 3Y44.44%
EPS Next 5Y34.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year599.08%
Revenue Next 2Y257.97%
Revenue Next 3Y174.3%
Revenue Next 5Y94.57%
EBIT growth 1Y17.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.09%
EBIT Next 3Y26.91%
EBIT Next 5Y20.15%
FCF growth 1Y1.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.54%
OCF growth 3YN/A
OCF growth 5YN/A